Compass Pathways and its potential magic mushroom depression drug went public last week – and now Mind Medicine is aiming to follow suit by up-listing its shares on the Nasdaq.
UK biotech Compass Pathways is planning a $100 million US IPO as it seeks to further develop its depression treatment based on psilocybin – an active ingredient that can be found in magic mushrooms.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback